Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan E Bates

Showing results (271-280 of 293) with videos related to

Pageof 30
Sort By:
Clinical Pharmacology and Therapeutics|August 8, 2006
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinibErin R Gardner, Herman Burger, Ron H van Schaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2014
A phase i study of DMS612, a novel bifunctional alkylating agentLeonard J Appleman, Sanjeeve Balasubramaniam, Robert A Parise, et al.
Journal of the National Cancer Institute|September 22, 2018
Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and NeckJoshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinomaSusan E Bates, Susan Bakke, Min Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patientsErin R Lepper, Sharyn D Baker, Matt Permenter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2015
Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphomaSalvia Jain, Xavier Jirau-Serrano, Kelly M Zullo, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|October 17, 2025
Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinomaMaryam Safari, Luigi Scotto, Agnes Basseville, et al.
Cancer Research|July 4, 2012
Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cellsMary Zhang, Aarti Mathur, Yuwei Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2010
Impact of ABCB1 allelic variants on QTc interval prolongationTristan M Sissung, Erin R Gardner, Richard L Piekarz, et al.
Blood|March 1, 2011
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaRichard L Piekarz, Robin Frye, H Miles Prince, et al.
Pageof 30

Showing results (271-280 of 293) with videos related to

Sort By:
Pageof 30
Clinical Pharmacology and Therapeutics|August 8, 2006
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinibErin R Gardner, Herman Burger, Ron H van Schaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2014
A phase i study of DMS612, a novel bifunctional alkylating agentLeonard J Appleman, Sanjeeve Balasubramaniam, Robert A Parise, et al.
Journal of the National Cancer Institute|September 22, 2018
Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and NeckJoshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinomaSusan E Bates, Susan Bakke, Min Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patientsErin R Lepper, Sharyn D Baker, Matt Permenter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2015
Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphomaSalvia Jain, Xavier Jirau-Serrano, Kelly M Zullo, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|October 17, 2025
Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinomaMaryam Safari, Luigi Scotto, Agnes Basseville, et al.
Cancer Research|July 4, 2012
Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cellsMary Zhang, Aarti Mathur, Yuwei Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2010
Impact of ABCB1 allelic variants on QTc interval prolongationTristan M Sissung, Erin R Gardner, Richard L Piekarz, et al.
Blood|March 1, 2011
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaRichard L Piekarz, Robin Frye, H Miles Prince, et al.
Pageof 30